BOLD · Boundless Bio Inc

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

10955 Alexandria Way, San Diego, CA, 92121, United States
Biotechnology
Healthcare

Market Cap

56.9M

52 Wk Range

$0.96 - $3.16

Previous Close

$2.41

Open

$2.43

Volume

152,851

Day Range

$2.38 - $2.43

Enterprise Value

-5.991M

Cash

62.89M

Avg Qtr Burn

-10.88M

Insider Ownership

12.12%

Institutional Own.

65.90%

Qtr Updated

Sep 30th 2026